United Therapeutics price target lowered to $262 from $264 at Ladenburg

Ladenburg analyst Matthew Kaplan lowered the firm’s price target on United Therapeutics to $262 from $264 and keeps a Buy rating on the shares based on updated projections driven by the Q4 results. The firm expects the growth of treprostinil-based products to largely be driven by the growing market potential for Tyvaso and continues to believe the Tyvaso DPI represents an attractive alternative to the current nebulizer for Tyvaso patients and “could be a significant driver for the future expanded uptake of Tyvaso,” the analyst tells investors.